Ensol Biosciences, Inc. manufactures and sells drugs. The firm develops BT·IT convergence technology (the core bioinformatics technology) such as in-silico genome analysis system, transcriptome analysis system, proteome analysis system and metabolome analysis system. It has been investing in developing bio-hydrogen energy, bio-environments, bio-foods and bio-cosmetics. The company was founded by Hae-Jin Kim on February 20, 2001 and is headquartered in Daejeon, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company